Biotech's are judged by their clinical trials results. LL's trial results have shown lack of success meeting endpoints or having competitive results.
Thus the lack of partners and lack of share price response when trial results are announced (mTNBC, NASH 350 mg). CoV failed to meet ANY endpoints, Long-CoV also ("directional" results). Folks want to tout the drug but so far has had very poor clinical trial results. Even the HIV combo results were not accepted for BTD and now Gilead has a drug that is a BTD and has better efficacy, dosing and equal safety.
Market Data 
Markets 
AI
